Event / FDA#327tier 2experimental liveNew
fast track designation long
cadence: Dailydata: mediumlong only
paper
2017
Source
Mostaghim, S.R., Gagne, J.J. & Kesselheim, A.S. (2017). "Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: Retrospective cohort study." BMJ, 358:j3837.
Read the paper →
What it checks
When the FDA grants a Fast-Track or Priority Review designation, we go long the sponsor for the next 2-3 months.
Mechanism
FDA expedited-pathway designations (Fast-Track, Breakthrough Therapy, Priority Review) compress timeline and signal regulator's unmet-need view; sponsor stock reprices ~+5% on designation, +8% over 60d.
No production champion data for this family yet. Stats appear once the discovery pipeline promotes at least one strategy with this family tag, or once a multi-family blend that includes it earns a champion slot.
Signal rule
First (ticker, drug_name) appearance in fda_adcomm -> LONG sponsor T+1 (announcement = min(first_ingest, first_action_date - 180d)); hold 20/40/60 trading days.
Data dependencies
daily_pricesAdjusted-close OHLCV for every US-listed ticker; primary price feed.
fda_adcommWorker data table — see services/worker schema.
Expected edge
- Paper alpha
- +5% event-day, +8% over 60d
- Paper window
- T+1 to T+60d
Mostaghim-Gagne-Kesselheim 2017: +5% event-day, +8% over 60d.
Example tickers where this is likely to fire
Illustrative only — the signal fires based on the live data, not a fixed list.
Related families
Explore fast track designation long on alphactor.ai
See which tickers this family is currently firing on, with live signals and rankings.